Erasca’s shares plunged after a phase I interim update for ERAS-0015, a pan-RAS molecular glue tested in RAS-mutant solid tumors including non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The company disclosed results from its ongoing Auroras-1 study in the US and a China experiment underway in collaboration with Joyo Pharmatech. Reporting on the reaction to the data pointed to a patient death from pneumonitis, which raised investor concerns about tolerability alongside early efficacy claims. Other investors are now comparing how ERAS-0015 stacks up against similar RAS-pathway programs. The update arrived as the company emphasized it is still collecting data and continues trial activities across geographies.